Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series

Annals of Surgical Oncology

Volumn 22, Issue 7, 2015, Pages 2286-2294

  Sapisochin, G ^a,b   Goldaracena, N ^a   Astete, S ^b   Laurence, J M ^a   Davidson, D ^a   Rafael, E ^c   Castells, L ^b   Sandroussi, C ^d   Bilbao, I ^b   Dopazo, C ^b   Grant, D R ^a   Lazaro J L ^b   Caralt, M ^b   Ghanekar, A ^a   McGilvray, I D ^a   Lilly, L ^e   Cattral, M S ^a   Selzner, M ^a   Charco, R ^b   Greig, P D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; SORAFENIB; TACROLIMUS;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; FOLLOW UP; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; ADULT; ADVERSE EFFECTS; AGED; BEHAVIOR; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; EPIDEMIOLOGY; ETIOLOGY; EUROPE; FEMALE; HUMAN; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTENTION; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84930483026     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4273-6     Document Type: Article

References (22)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;31:1245–55.
2. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982–9.
3. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.
5. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166–72.
6. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.
7. Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39.
8. Cillo U, Vitale A, Grigoletto F, Gringeri E, D’Amico F, Valmasoni M, Brolese A, et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transpl. 2007;7:972–81.
9. Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, Giostra E, et al. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci. 2013;20:342–7.
10. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge. Transpl Int. 2013;26:109–18.
11. DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13:24–32.
12. Wo JY, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:353–68.
13. Sapisochin G, Castells L, Dopazo C, Bilbao I, Minguez B, Lázaro JL, Allende H, et al. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol. 2013;20:1194–202.
14. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, Fernandez JR, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transpl Proc. 2010;42:660–2.
15. Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori. 2011;97:436–41.
16. Taketomi A, Toshima T, Kitagawa D, Motomura T, Takeishi K, Mano Y, Kayashima H, et al. Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2010;17:2740–6.
17. Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol. 2013;59:3–5.
18. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Willberg J. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol. 2010;36:275–80.
19. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534–44.
20. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein >1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting Milan criteria. Liver Transpl. 2014.
21. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, et al; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.
22. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330–9.